Document is current

Article History

Received: 23 November 2023

Accepted: 21 August 2024

First Online: 17 September 2024

Declarations

:

: This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice published by the International Society for Pharmacoepidemiology. This study used de-identified retrospective electronic health record data from the Optum® Research Database, therefore no specific ethical approval was required.

: Not applicable.

: Noa Krugliak Cleveland served as a consultant for Arena Pharmaceuticals, Bristol Myers Squibb, and Takeda Pharmaceuticals U.S.A., Inc. Benjamin Chastek and Tim Bancroft are employees of Optum. Sabyasachi Ghosh is a former employee of Takeda Pharmaceuticals U.S.A, Inc. and has stock or stock options. Ninfa Candela and Tao Fan are employees of Takeda Pharmaceuticals U.S.A., Inc. and hold stock or stock options. Kandavadivu Umashankar is an employee of University of Illinois, Chicago, IL, USA, who was supported by a Takeda Pharmaceuticals U.S.A., Inc. fellowship at the time of the study. David T. Rubin received grant support from Takeda Pharmaceuticals U.S.A., Inc. and has served as a consultant for AbbVie, AltruBio, Arena Pharmaceuticals, Bristol Myers Squibb, Genentech/Roche, Gilead Sciences, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Biosciences, Takeda, and TechLab Inc.